Evidence map›Paper›PMID 36991144›Full record

ArticleNPJ digital medicine2023

A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases.

Alexandros Rekkas, David van Klaveren, Patrick B Ryan, Ewout W Steyerberg, David M Kent, Peter R Rijnbeek

Open access · goldAbstract read
In one paragraph

Article in NPJ digital medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
9.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Characterizing Treatment Effect Heterogeneity Using Real-World Data.Clinical pharmacology and therapeutics · 2025
    Review
  4. Article
  5. The R.O.A.D. to precision medicine.NPJ digital medicine · 2024
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Alexandros RekkasDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. a.rekkas@erasmusmc.nl.ORCID http://orcid.org/0000-0002-5352-943X
David van KlaverenDepartment of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Patrick B RyanJanssen Research and Development, 125 Trenton Harbourton Road, Titusville, NJ, 08560, USA.
Ewout W SteyerbergDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-7787-0122
David M KentPredictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9205-5070
Peter R RijnbeekDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLTufts Medical Center · USColumbia University Irving Medical Center · USLeiden University Medical Center · NL

Funding

Innovative Medicines Initiative (IMI) 80696
6 · The paper itself

Abstract

Treatment effects are often anticipated to vary across groups of patients with different baseline risk. The Predictive Approaches to Treatment Effect Heterogeneity (PATH) statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of treatment effect heterogeneity in a randomized controlled trial. The aim of this study is to extend this approach to the observational setting using a standardized scalable framework. The proposed framework consists of five steps: (1) definition of the research aim, i.e., the population, the treatment, the comparator and the outcome(s) of interest; (2) identification of relevant databases; (3) development of a prediction model for the outcome(s) of interest; (4) estimation of relative and absolute treatment effect within strata of predicted risk, after adjusting for observed confounding; (5) presentation of the results. We demonstrate our framework by evaluating heterogeneity of the effect of thiazide or thiazide-like diuretics versus angiotensin-converting enzyme inhibitors on three efficacy and nine safety outcomes across three observational databases. We provide a publicly available R software package for applying this framework to any database mapped to the Observational Medical Outcomes Partnership Common Data Model. In our demonstration, patients at low risk of acute myocardial infarction receive negligible absolute benefits for all three efficacy outcomes, though they are more pronounced in the highest risk group, especially for acute myocardial infarction. Our framework allows for the evaluation of differential treatment effects across risk strata, which offers the opportunity to consider the benefit-harm trade-off between alternative treatments.

Identifiers

PMID36991144
PMCPMC10060247
OpenAlexW4361283651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.